Metabolic hormone ‘leptin’ linked to poor vaccine response
Reduced levels of a metabolic hormone known as leptin is linked to poor vaccine antibody responses in the general population, a University of Queensland study has found. The… read more.
Reduced levels of a metabolic hormone known as leptin is linked to poor vaccine antibody responses in the general population, a University of Queensland study has found. The… read more.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced efficacy and safety data for Stelara (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),including data from the SEAVUE… read more.
Novartis,has announced the FDA has approved Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for… read more.
Organon celebrates its launch as a global women’s health company with employees and women from around the world, as the Organon executive leadership team rings the opening bell… read more.
People who have had mild illness develop antibody-producing cells that can last lifetime Washington University School of Medicine Months after recovering from mild cases of COVID-19, people still… read more.
Ad26.COV2-S [recombinant] a single-dose coronavirus vaccine from Janssen, part of Johnson & Johnson, has been approved by the MHRA (UK) and is indicated for active immunisation to prevent… read more.
Bristol Myers Squibb announced that the FDA has approved Opdivo (nivolumab, injection for intravenous use) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer… read more.
Surprisingly, despite widespread use, no one understood exactly how most mosquito repellents keep the insects away. Now researchers are starting to uncover the first pieces of the puzzle…. read more.
The four-year project took samples from patients hospitalised with influenza at up to five time points during their hospital stay, and 30 days after discharge. They analysed the… read more.
Horizon Therapeutics plc announced the publication of a new analysis of the pivotal Phase II/III N-MOmentum trial for Uplizna (inebilizumab-cdon), assessing the potential for reduced risk of worsening… read more.
An influenza vaccine that is made of nanoparticles and administered through the nose enhances the body’s immune response to influenza virus infection and offers broad protection against different… read more.
AstraZeneca’s Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.